Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Adma Biologics (ADMA) over the last 8 years, with Q3 2025 value amounting to -$2.2 million.

  • Adma Biologics' Other Non Operating Income fell 378750.0% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 10385.51%. This contributed to the annual value of $4.3 million for FY2024, which is 11658.13% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Other Non Operating Income is -$2.2 million, which was down 378750.0% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Other Non Operating Income ranged from a high of $4.4 million in Q4 2024 and a low of -$26.0 million during Q4 2023
  • In the last 5 years, Adma Biologics' Other Non Operating Income had a median value of -$42001.0 in 2021 and averaged -$1.7 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 17014.37% in 2021, then crashed by 4404735762.71% in 2023.
  • Quarter analysis of 5 years shows Adma Biologics' Other Non Operating Income stood at -$145228.0 in 2021, then skyrocketed by 99.96% to -$59.0 in 2022, then tumbled by 44047357.63% to -$26.0 million in 2023, then soared by 117.11% to $4.4 million in 2024, then tumbled by 148.95% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, -$1.2 million for Q2 2025, and -$64000.0 during Q1 2025.